The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.
Age 18-60 for the main trial cohort
Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort
First diagnosis of treatment-naïve cHL
large mediastinal mass
Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and/or central nervous system involvement of lymphoma